Compare SQNS & IXHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SQNS | IXHL |
|---|---|---|
| Founded | 2003 | 2001 |
| Country | France | Australia |
| Employees | N/A | N/A |
| Industry | Semiconductors | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 85.3M | 97.6M |
| IPO Year | 2011 | 2024 |
| Metric | SQNS | IXHL |
|---|---|---|
| Price | $3.09 | $4.98 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $20.33 | N/A |
| AVG Volume (30 Days) | 118.4K | ★ 4.5M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $12,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $62.85 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.73 | $0.11 |
| 52 Week High | $10.93 | $5.17 |
| Indicator | SQNS | IXHL |
|---|---|---|
| Relative Strength Index (RSI) | 43.49 | 87.75 |
| Support Level | $2.72 | $0.31 |
| Resistance Level | $5.85 | $5.17 |
| Average True Range (ATR) | 0.20 | 0.33 |
| MACD | 0.10 | 0.36 |
| Stochastic Oscillator | 83.64 | 89.24 |
Sequans Communications SA is a designer, developer, and supplier of cellular semiconductor solutions for broadband Internet of Things (IoT) markets. Its offer 5G/4G chips and modules fully optimized for non-smartphone devices. The company covers applications such as smart mobility and logistics, smart utility meters, smart cities, smart industries, e-health and wellness, and smart homes to name few. The Company has one operating segment, which is the design and marketing of semiconductor components for cellular wireless systems. Its geographical segments are Taiwan, Korea, China (including Hong Kong), the Rest of Asia, the United States and the Rest of the world.
Incannex Healthcare Inc is a clinical stage pharmaceutical company developing medical cannabis products for the treatment of Obstructive Sleep Apnea (OSA), Traumatic Brain Injury (TBI)/Concussion, Rheumatoid Arthritis, Inflammatory Bowel Disease, and Inflammatory Lung Conditions. The company has an Australian license to import, export, and distribute medicinal cannabis products and has launched a line of cannabinoid products. The Company operates and manages its business as one reportable and operating segment, which is the Research and Development of the use of psychedelic medicine and therapies.